Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus
Main finding · Composite renal outcomeResult — go to the resultHazard ratio 0.489 95 % CI 0.271–0.883Authors' conclusion
The use of GLP1-RAs decreased the risk of a composite outcome of renal dysfunction and mortality, improved metabolic control and showed safety of use in a large cohort of diabetic KTR, suggesting reno-protective effects in this high-risk population. Prospective data is further needed in KTR who are excluded from large RCTs.
Study context
- Population
- Adult kidney transplant recipients (KTR) with DM; 69 % males, average age 58.3 ± 11.0 yearsmatched cohort
- Participants
- 272 recipients
- Exposure
- GLP-1 RA users vs matched non-users
- Outcome
- Composite of:
- First occurrence of graft rejection
- Start of dialysis
- Re-transplantation
- All-cause mortality
- Follow-up
- 3.1-year median
Methodological detailsmatched
- Matched
Main finding
Composite renal outcome
Hazard ratio
0.489
95 % CI 0.271–0.883
By group
Controls
114 events per 1000-patient years
GLP1-RA users
68 events per 1000-patient years
GLP1-RA usersvs Controls
HR 0.489 (95 % CI 0.271–0.883)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Metabolic effects
- GLP-1 RA users had improved glycemic control, lipid profile and a decrease in BMI
Safety
- Treatment was safe without increased genitourinary infections or biliopancreatic events
Original publication
Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus. Diabetes Metab. Published 15 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →